JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies

  • 0Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Frontiers in Immunology +

|

February 3, 2025

|

February 3, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

High-grade serous ovarian cancer (HGSOC) research identifies a C2 IGF2+ tumor subtype linked to poor prognosis. This finding offers potential for targeted therapies and improved patient outcomes in ovarian cancer treatment.

Area Of Science

  • Oncology
  • Cancer Immunology
  • Genomics

Background

  • High-grade serous ovarian cancer (HGSOC) often presents at advanced stages with limited survival improvements from current treatments.
  • Understanding HGSOC's molecular mechanisms, immune microenvironment, and drug sensitivity is vital for developing personalized therapies.

Purpose Of The Study

  • To investigate HGSOC tumor heterogeneity and immune interactions using single-cell RNA sequencing (scRNA-seq).
  • To identify novel therapeutic targets and biomarkers influencing drug response and immune activity in HGSOC.
  • To develop a prognostic model for assessing prognosis, immune infiltration, and drug sensitivity.

Main Methods

  • Analysis of scRNA-seq data from the GEO database.
  • Differential gene expression analysis, gene ontology, and gene set enrichment.
  • Identification of malignant cells, differentiation trajectories, cellular communication, and transcription factor networks using specialized software (InferCNV, Monocle, CellChat, pySCENIC).

Main Results

  • The C2 IGF2+ tumor subtype was confirmed as a key driver of HGSOC, associated with poor prognosis and high chromosomal instability.
  • This subtype, found at the terminal differentiation stage, showed increased malignancy and links to metabolic pathways and programmed cell death.
  • Interactions between the C2 subtype and fibroblasts via the MK signaling pathway were highlighted, alongside elevated PRRX1 expression impacting disease progression.

Conclusions

  • The study integrates molecular, immunological, and drug sensitivity data to elucidate HGSOC progression and resistance mechanisms.
  • The C2 IGF2+ subtype presents a promising therapeutic target for HGSOC.
  • Personalized strategies focusing on immune infiltration and drug sensitivity are crucial for improving HGSOC patient survival and quality of life.

Keywords: